Guidance

UK parallel import licences following agreement of the Windsor Framework

Information relating to parallel imports and the implementation of the Windsor Framework.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 5 April 2024
• Last updated: 11 March 2025 — See all updates

Applies to England, Scotland and Wales

Documents

UK parallel import licences following agreement of the Windsor Framework

HTML

Notification of Stickering on Parallel Import Licences

MS Word Document, 79.7 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Parallel Distribution Notices (PDNs) are notice letters which parallel distributors must obtain from the European Medicines Agency before placing a centrally authorised product on the market. PDNs are no longer valid in Great Britain (England, Scotland, Wales). These were replaced by Parallel Import Licences (PLPIs) through the PDN to PLPI conversion process, which allow the products to be marketed in Great Britain (GB) only. PDNs currently remain valid in Northern Ireland.

Published 5 April 2024

Last updated 11 March 2025 + show all updates

1. 11 March 2025

   Updated to remove: “1. Subject to the UK providing written guarantees to the European Commission as provided for in Article 8 of EU Regulation 2023/1182 and following the entry into force and application procedure provided for in Article 14” from document UK Parallel Import Licences Following Agreement of the Windsor Framework

2. 5 April 2024

   First published.